Vaxart, Inc. (VXRT)

Market Cap	135.60M
Revenue (ttm)	16.76M
Net Income (ttm)	-72.34M
Shares Out	227.48M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	553,180
Open	0.599
Previous Close	0.620
Day's Range	0.582 - 0.636
52-Week Range	0.520 - 1.540
Beta	0.62
Analysts	Strong Buy
Price Target	3.00 (+403.27%)
Earnings Date	Nov 13, 2024

About VXRT

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Steven Lo
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: VXRT
• Website: https://vaxart.com

Financial Performance

In 2023, Vaxart's revenue was $7.38 million, an increase of 6796.26% compared to the previous year's $107,000. Losses were -$82.47 million, -23.47% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for VXRT stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 403.27% from the latest price.

Price Target

$3.0

(403.27% upside)

Analyst Consensus: Strong Buy